AnaptysBio Statistics
Total Valuation
AnaptysBio has a market cap or net worth of $662.82 million. The enterprise value is $668.84 million.
Important Dates
The last earnings date was Monday, May 5, 2025, after market close.
| Earnings Date | May 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AnaptysBio has 29.38 million shares outstanding. The number of shares has increased by 10.16% in one year.
| Current Share Class | 29.38M |
| Shares Outstanding | 29.38M |
| Shares Change (YoY) | +10.16% |
| Shares Change (QoQ) | +0.64% |
| Owned by Insiders (%) | 2.20% |
| Owned by Institutions (%) | 98.55% |
| Float | 17.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.92 |
| Forward PS | 18.38 |
| PB Ratio | 20.15 |
| P/TBV Ratio | 19.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.98 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.25, with a Debt / Equity ratio of 10.17.
| Current Ratio | 8.25 |
| Quick Ratio | 8.13 |
| Debt / Equity | 10.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.62 |
Financial Efficiency
Return on equity (ROE) is -343.83% and return on invested capital (ROIC) is -16.60%.
| Return on Equity (ROE) | -343.83% |
| Return on Assets (ROA) | -15.14% |
| Return on Invested Capital (ROIC) | -16.60% |
| Return on Capital Employed (ROCE) | -26.53% |
| Revenue Per Employee | $822,588 |
| Profits Per Employee | -$1.03M |
| Employee Count | 136 |
| Asset Turnover | 0.27 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AnaptysBio has paid $47,000 in taxes.
| Income Tax | 47,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -3.42% in the last 52 weeks. The beta is -0.20, so AnaptysBio's price volatility has been lower than the market average.
| Beta (5Y) | -0.20 |
| 52-Week Price Change | -3.42% |
| 50-Day Moving Average | 19.55 |
| 200-Day Moving Average | 23.13 |
| Relative Strength Index (RSI) | 65.14 |
| Average Volume (20 Days) | 542,692 |
Short Selling Information
The latest short interest is 8.83 million, so 30.06% of the outstanding shares have been sold short.
| Short Interest | 8.83M |
| Short Previous Month | 8.96M |
| Short % of Shares Out | 30.06% |
| Short % of Float | 50.03% |
| Short Ratio (days to cover) | 16.01 |
Income Statement
In the last 12 months, AnaptysBio had revenue of $111.87 million and -$140.62 million in losses. Loss per share was -$4.79.
| Revenue | 111.87M |
| Gross Profit | -56.11M |
| Operating Income | -100.29M |
| Pretax Income | -170.11M |
| Net Income | -140.62M |
| EBITDA | -99.70M |
| EBIT | -100.29M |
| Loss Per Share | -$4.79 |
Full Income StatementBalance Sheet
The company has $339.94 million in cash and $345.96 million in debt, giving a net cash position of -$6.02 million or -$0.20 per share.
| Cash & Cash Equivalents | 339.94M |
| Total Debt | 345.96M |
| Net Cash | -6.02M |
| Net Cash Per Share | -$0.20 |
| Equity (Book Value) | 34.02M |
| Book Value Per Share | 1.12 |
| Working Capital | 319.08M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$108.78 million and capital expenditures -$366,000, giving a free cash flow of -$109.15 million.
| Operating Cash Flow | -108.78M |
| Capital Expenditures | -366,000 |
| Free Cash Flow | -109.15M |
| FCF Per Share | -$3.72 |
Full Cash Flow StatementMargins
Gross margin is -50.15%, with operating and profit margins of -89.64% and -125.70%.
| Gross Margin | -50.15% |
| Operating Margin | -89.64% |
| Pretax Margin | -125.66% |
| Profit Margin | -125.70% |
| EBITDA Margin | -89.12% |
| EBIT Margin | -89.64% |
| FCF Margin | n/a |
Dividends & Yields
AnaptysBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.16% |
| Shareholder Yield | -10.16% |
| Earnings Yield | -21.22% |
| FCF Yield | -16.47% |
Analyst Forecast
The average price target for AnaptysBio is $42.25, which is 87.28% higher than the current price. The consensus rating is "Buy".
| Price Target | $42.25 |
| Price Target Difference | 87.28% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 11.02% |
| EPS Growth Forecast (5Y) | 0.79% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AnaptysBio has an Altman Z-Score of -1.15 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.15 |
| Piotroski F-Score | 3 |